1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. SI-BONE, Inc.
  6. News
  7. Summary
    SIBN   US8257041090

SI-BONE, INC.

(SIBN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Needham Names SI-Bone 2022 Top Pick, Citing Outpatient Exposure, iFuse-TORQ Potential; Conviction Buy Rating, $32 Price Target Reiterated

12/13/2021 | 05:55am EDT


© MT Newswires 2021
All news about SI-BONE, INC.
05/11TRANSCRIPT : SI-BONE, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-..
CI
05/10SI-BONE, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/10Morgan Stanley Adjusts SI-Bone's Price Target to $22 from $28, Keeps Overweight Rating
MT
05/10Needham Adjusts SI-Bone's Price Target to $28 From $30, Citing Peer Multiple Contractio..
MT
05/09SI-Bone Reports Wider Loss, Higher Revenue in Q1
MT
05/09TRANSCRIPT : SI-BONE, Inc., Q1 2022 Earnings Call, May 09, 2022
CI
05/09SI-BONE : Q1 Earnings Snapshot
AQ
05/09Earnings Flash (SIBN) SI-BONE Reports Q1 Revenue $22.4M, vs. Street Est of $21.9M
MT
05/09SI-BONE, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/09SI-BONE, Inc. Reports First Quarter 2022 Financial Results
AQ
More news
Analyst Recommendations on SI-BONE, INC.
More recommendations
Financials (USD)
Sales 2022 107 M - -
Net income 2022 -64,5 M - -
Net cash 2022 56,3 M - -
P/E ratio 2022 -7,16x
Yield 2022 -
Capitalization 458 M 458 M -
EV / Sales 2022 3,74x
EV / Sales 2023 3,41x
Nbr of Employees 352
Free-Float 98,2%
Chart SI-BONE, INC.
Duration : Period :
SI-BONE, Inc. Technical Analysis Chart | SIBN | US8257041090 | MarketScreener
Technical analysis trends SI-BONE, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 13,50 $
Average target price 25,43 $
Spread / Average Target 88,4%
EPS Revisions
Managers and Directors
Laura A. Francis Chief Executive Officer & Director
Anshul Maheshwari Chief Financial & Accounting Officer
Jeffrey W. Dunn Executive Chairman
Scott A. Yerby Chief Technology Officer & Senior VP-Engineering
W. Carlton Reckling Vice President-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
SI-BONE, INC.-39.22%458
MASIMO CORPORATION-51.71%7 847
GETINGE AB-27.89%7 826
NOVOCURE LIMITED-0.51%7 745
SHOCKWAVE MEDICAL, INC.-11.25%5 735
PENUMBRA, INC.-50.59%5 363